Indonesia hospital market: fragmented nationally, oligopolistic locally
Indonesia's private hospital sector is paradoxical. At the national level, the four-firm concentration ratio (CR4) sits below 40 [JAKI 2024] — textbook fragmentation in a market of 2,820 hospitals where government facilities hold 51.4% of the institutional count [JAKI 2024]. At the provincial and catchment level, the picture is almost the opposite: in many second-tier cities, a single chain or government complex holds CR4 above 90, making local competitive dynamics closer to oligopoly than the national average suggests.
This duality explains the consolidation thesis that patient capital — Djarum, Quadria, TPG — is now moving on: acquisitions earn most of their value at the catchment level, not the national level, and the national CR4 below 40 leaves enormous room for roll-up before regulatory intervention becomes a risk.
The private-bed pool: 180,000 beds, 10% chain-controlled
Indonesia's 1,787 private hospitals (63.5% of the national 2,820 stock) hold an estimated 180,000 beds [Databoks 2025, Kira estimates]. The top 10–15 chains operate approximately 10% of that pool — roughly 18,000 beds across named operators. The remaining 90% is held by independent single-site or small-cluster operators, the majority of which are faith-based, cooperative-owned, or physician-founded community hospitals with limited access to capital markets.
The KRIS reform (Perpres 59/2024) — which mandates 12 facility-quality upgrades across all JKN-collaborating hospitals — will accelerate this fragmentation into a consolidation catalyst. Sub-scale operators face capex bills for ventilation upgrades, oxygen outlet installations, room-separation works, and accessible bathroom retrofits that their cash flows cannot absorb without debt or equity capital. Price discovery for these assets will be most favourable in the next 12–18 months, before KRIS compliance becomes a binary pass/fail condition for BPJS contracting.
Top-5 private chain bed footprint (2025)
The four operating models
Hermina (IDX: HEAL) — BPJS-anchored breadth. 52 hospitals across 63 cities in 17 provinces, the broadest geographical footprint of any private chain [HEAL FY2024]. Revenue mix approximately 70% BPJS [Quadria 2025]. Djarum's Dwimuria vehicle purchased approximately Rp 1.04 trillion at Rp 1,875 per share in June 2025 [Suara 2025]; Quadria Capital has been on the register since 2017. The entry of two patient-capital vehicles into a BPJS-anchored operator is the clearest signal that the payer-anchored model — once dismissed as low-margin — is now being underwritten as a long-duration asset.
Siloam (IDX: SILO) — premium and tertiary scale. 41 hospitals; 9M25 revenue Rp 9.43 trillion (+3.3% YoY); underlying EBITDA margin 29.2% [SILO 9M2025]. JCI accreditation at flagship sites supports the private-pay tilt. Siloam's premium positioning insulates it more than peers from the KRIS class-1 compression: the revenue at risk from eliminating class-1 differentiation is smaller as a share of its payor mix.
Mitra Keluarga (IDX: MIKA) — high-margin Greater Jakarta density. ~25 hospitals concentrated in Jabodetabek and Surabaya. FY24 revenue Rp 4.87 trillion (+14.3% YoY); net income Rp 1.15 trillion (+25.1% YoY) [MIKA FY2024]. Highest profitability in the listed cohort. Corporate-insured and cash-pay payor mix means limited BPJS deficit exposure.
Mayapada (IDX: SRAJ) — high-end tertiary positioning. ~12 hospitals in greater Jakarta and Tangerang catchments. Group affiliate exposure to the Bali Sanur medical-tourism SEZ positions Mayapada as a potential beneficiary of outbound-patient repatriation if premium international patients can be attracted back onshore.
Capital signals: who is buying and why
Three transactions in 2024–2025 define the investment thesis that institutional capital is writing on Indonesian hospital assets:
- Djarum → Hermina (Jun 2025): Rp 1.04 tn at Rp 1,875/share [Suara 2025]. Djarum's Dwimuria vehicle is a conglomerate arm that has historically moved early on domestic consumer-facing businesses. The bet is that BPJS-anchored breadth, paired with iDRG coding discipline, produces durable throughput economics at scale.
- Quadria Capital → Hermina (existing stake, upped 2025): Healthcare-specialist PE with regional SEA track record [DealStreetAsia 2025]. 10 million patients per year through Hermina's 52-hospital network is the asset being underwritten [Quadria 2025].
- TPG → Columbia Asia: Global buyout firm owning the mid-market Columbia Asia chain, which operates across Indonesia, Malaysia, and Vietnam. Signals that cross-border hospital platforms are being assembled at the PE level.
The common thread: each buyer is positioning ahead of KRIS-driven sub-scale operator exits and iDRG tariff transparency. Fragmented sellers, regulatory pressure-induced supply, and a market at ~10% chain penetration of private beds create a multi-year roll-up runway.
Strategic convergence under KRIS
Despite their different starting positions, KIRA's analysis suggests the three listed chains are converging on the same three operational levers over 2026–2028:
- Day-care and ambulatory expansion — as class-1 inpatient differentiation compresses, the margin wedge shifts to shorter-stay, higher-throughput services where private willingness-to-pay holds.
- iDRG coding capability — the INA-CBGs to iDRG migration introduces severity weighting with a 46–75% tariff variance on common procedures [JFSP 2025]. Operators with clinical-documentation AI and trained coding staff capture the upside; those without absorb the squeeze.
- Clinical AI deployment on the SATUSEHAT base — 96% EMR adoption and 92% SATUSEHAT integration [Kemenkes 2025] mean the data layer is available. Imaging triage, sepsis early-warning, and patient-flow optimisation are the workflow tools that convert data infrastructure into margin.
Sources: JAKI 2024 (Jurnal Administrasi Kesehatan Indonesia HHI Study); Databoks Katadata Hospital Ownership Census 2025; Perpres 59/2024 (Presidential Regulation KRIS); HEAL FY2024 (Medikaloka Hermina Annual Report); SILO 9M2025 (Siloam International 9M2025 Filing); MIKA FY2024 (Mitra Keluarga Annual Report 2024); Quadria Capital Indonesia Note 2025; DealStreetAsia Quadria-Hermina Deal Note 2025; Suara.com Djarum Hermina Acquisition 2025; JFSP 2025 (Jurnal Farmasi Sains Praktis INA-CBGs Variance Study); Kemenkes 2025 (SATUSEHAT EMR Statistics); KIRA analyst triangulation.